Y-Biologics

About:

Y-Biologics is specialized in antibody drug since its inception has focused on research and development

Website: http://ybiologics.com/

Top Investors: Mirae Asset Securities, HK inno.N, Smilegate Investment, IMM Investment, Kolon Investment

Description:

Y-Biologics is specialized in antibody drug since its inception has focused on research and development. They have successfully constructed the unique human antibody library Y-max ABL and new dual antibody platform technology ALiCE. Based on this, they have developed various antibody drugs and become a leading company in the global immuno-chemotherapeutic drug market They are doing their best to leap forward.

Total Funding Amount:

30B KRW

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Seoul, Seoul-t'ukpyolsi, South Korea

Founded Date:

2007-01-01

Contact Email:

info(AT)ybiologics.com

Founders:

Number of Employees:

51-100

Last Funding Date:

2022-02-24

IPO Status:

Private

Industries:

© 2025 bioDAO.ai